Last Price: $22.95 , UP $2.30 (11.11%)
Gold Resource Corporation Executes $55.6 Million Private Placement to Accelerate Production Profile and Exploration
Gold Resource Corporation (GORO) (AMEX: GORO) is pleased to announce the execution of agreements for a $55.6 million private placement of its common stock to increase the development of its Oaxaca Mining Unit’s production profile, accelerate its exploration programs, initiate a formal reserve report and to capitalize on new property acquisition opportunities. Gold Resource Corporation is a low-cost gold producer with operations in southern Mexico.
Gold Resource Corporation’s private placement consists of 3.475 million shares of restricted common stock at $16.00 per share with no warrants. Jefferies & Company, Inc. served as sole placement agent for Gold Resource Corporation in the private placement. Closing of the transaction is subject to customary conditions.
The Company intends to increase mill capacity by potentially 50% in anticipation of expansion of its known mineralization at the La Arista vein system and thereby correspondingly increase the Project’s production profile. The Company will accelerate exploration of the Oaxaca Mining Unit’s portfolio of 5 potential high-grade properties. Having drilled only 1% of the Oaxaca Mining Unit’s concessions to date, and finding three high-grade deposits, an aggressive investment in exploration is warranted and could have a positive, near-term impact on shareholder value. A more formal reserve report of the internally estimated mineralized material will be undertaken. And, the Company will also be in the position to acquire additional property opportunities located in select areas throughout Mexico and worldwide for project diversification and Company growth.
Gold Resource Corporation is positioned for accelerated and aggressive growth during this historic gold bull market. The equity raise provides immediate funding to accelerate the Company’s production profile and to accelerate exploration of its Oaxaca Mining Unit. Management believes the potential 50% mill capacity increase coupled with the ability to accelerate exploration programs on a more comprehensive and immediate basis more than offsets the 7% shareholder dilution. With only 53 million shares outstanding after the raise, the Company is among the tightest capital structures for a producing company in the mining space.
Gold Resource Corporation, an exploration stage company, engages in the exploration for and production of gold, silver, precious metals, and base metals, including copper, lead, and zinc primarily in Mexico. It holds a 100% interest in five properties, including the El Aguila property, the Las Margaritas property, the El Rey property, the Solaga property, and the Alta Gracia property in southern state of Oaxaca. The company was founded in 1998 and is based in Denver, Colorado.
http://www.goldresourcecorp.com
Last Trade: $64.45 , UP $1.79 (2.86%)
Park National Corporation Reports Second Quarter 2010 Financial Results and Declares Quarterly Cash Dividend
Park National Corporation (Park) (NYSE Amex:PRK) recently announced operating results for the three and six months ended June 30, 2010 (second quarter and first half of 2010). Park’s Board of Directors also today declared a $0.94 per common share quarterly cash dividend, payable on September 10, 2010 to common shareholders of record as of August 25, 2010.
“We are pleased to report business loan growth in the second quarter of this year. Also, extraordinarily low residential mortgage rates continue to help generate significant consumer lending activity, including $244 million in mortgage loan originations for the first half of 2010,” said Park Chairman C. Daniel DeLawder. “Our lenders are focused on supporting each community we serve through high-quality, reliable lending with consistent underwriting. As economic conditions slowly improve, we hope to further expand our loan balances and reduce problem credits.”
Park’s second quarter net income was $21.2 million, compared to $21.3 million for the same period in 2009. Net income was $41.9 million for first half of 2010, a 1.8 percent decline from the first half of 2009 net income of $42.7 million.
Net income for Park’s Ohio-based operations was $56.2 million for the first half of 2010, a 5.4 percent increase from the $53.3 million reported in the first half of 2009. Net income for Park’s Ohio-based operations was $27.9 million for the second quarter of 2010, the same as the $27.9 million reported in the second quarter of 2009.
Headquartered in Newark, Ohio, Park National Corporation has $7.1 billion in total assets (as of June 30, 2010). Park consists of 13 community bank divisions and two specialty finance companies. Park’s Ohio-based banking operations are conducted through Park subsidiary The Park National Bank and its divisions which include Fairfield National Bank Division, Richland Bank Division, Century National Bank Division, First-Knox National Bank Division, Farmers & Savings Bank Division, United Bank Division, Second National Bank Division, Security National Bank Division, Unity National Bank Division and The Park National Bank of Southwest Ohio & Northern Kentucky Division.
http://www.parknationalcorp.com
Proteonomix, Inc. (OTCBB: PROT.OB)
Last Trade: $1.85 , UP $0.23 (14.20%)
The Science Behind our Cutting-Edge Skin Care Products
How It Works
Proteoderm has used its expertise in protein technology to develop a unique, natural matrix of proteins called Matrix NC-138T for use in anti-aging skin products.
Matrix NC-138
Bioactive proteins have been defined as specific proteins that have a positive impact on body functions or conditions and may ultimately influence health.
The activity of these biofunctional proteins contained in the isolated Matrix NC-138T NC-138 is based on their inherent amino acid composition and sequence. MatrixNC-138T acts on the skin to enhance activities through the stimulation of collagen and glandular production leading to a reduction of wrinkles.
Anti-Aging Technology
This company may be able to reverse the signs of aging without Botox injections.
Proteoderm is another subsidiary of Proteonomix.
Proteoderm�s expertise in biotechnology led to the development of cutting edge anti-aging skin care products. The Proteoderm system works to revitalize and rejuvenate your own cells to help drastically reverse the effects of aging!
Among the many cosmetic actives available, proteins have garnered substantial interest for several years. The main reason is that one of the properties of proteins is the delivery of a chemical message that up or down regulates particular cell functions. An accepted view of protein activity is that their amino-acid constituents have structures which send specific signals to the specific cells, for example to the fibroblasts to increase collagen production.
Particular proteins are therefore ideal cosmetic ingredients that can be used to counteract the formation of wrinkles and loss of skin elasticity. Proteoderm has used its expertise in proteomics and protein technology to develop a unique natural matrix of proteins called MatrixTM NC-138 for use in anti-aging skin products.
About Proteonomix, Inc.
Proteonomix, Inc., a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products.
The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. It offers product for the treatment of anti-aging and damaged skin. The company develops cosmetic products using its technologies, Secreted Matrix and Matrix NC-138 that is a stem cell derived proteins technology.
It also involves in the operation of retail Web site, Proteoderm.com to sell its anti-aging line of skin care products; develops therapeutic modalities for the treatment of cardiovascular disease; and engages in the reproductive tissue banking, including sperm, ova, ovarian tissue, and testicular tissue.
In addition, the company develops intellectual properties for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a cord blood banking cryopreservation bag, and a device to eliminate malformed stem cells via filtration.
Further, it is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix was founded in 2005 and is based in Mountainside, New Jersey.
http://www.proteonomix.com/
No comments:
Post a Comment